Spironolactone and Bupropion Interaction

Why This Combination Comes Up Clinically

Women prescribed spironolactone 50 to 200 mg daily for hormonal acne frequently also take bupropion for depression, smoking cessation, or ADHD-adjacent symptoms. Bupropion (Wellbutrin, Zyban) is among the most prescribed antidepressants in the United States, with over 28 million dispensed prescriptions in 2022 according to ClinCalc drug usage data. Spironolactone use for acne has grown substantially since the 2020 publication of a large retrospective cohort (N=6,684) in the Journal of the American Academy of Dermatology confirming its efficacy and safety profile in women of reproductive age [1].

The Typical Patient Profile

The overlap population is predominantly women aged 18 to 45 who present with both moderate-to-severe hormonal acne and a mood disorder. Because SSRIs carry sexual side-effect profiles that may be unacceptable, bupropion becomes a preferred antidepressant in this demographic. Prescribers need to know whether these two medications interact before writing both on the same prescription pad.

Classification of the Interaction

Major drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) rate the spironolactone-bupropion combination as either "no interaction" or "minor." There is no black-box warning, no contraindication, and no dose-ceiling modification required by either the spironolactone or bupropion FDA-approved labeling [2][3].

Pharmacokinetic Analysis

The question of whether two drugs interact pharmacokinetically depends on shared metabolic pathways. Spironolactone and bupropion do not share meaningful enzymatic routes.

Spironolactone Metabolism

Spironolactone undergoes extensive first-pass hepatic metabolism. Its primary active metabolites are canrenone and 7-alpha-thiomethylspironolactone. The metabolic pathway involves deacetylation, dethioacetylation, and sulfur oxidation reactions that are largely mediated by flavin-containing monooxygenases (FMOs) and carboxylesterases rather than cytochrome P450 enzymes [4]. While some in vitro data suggest minor CYP3A4 involvement, spironolactone is not classified as a CYP2D6 substrate.

Bupropion Metabolism and CYP2D6 Inhibition

Bupropion is metabolized primarily by CYP2B6 to its active metabolite hydroxybupropion. It is a potent inhibitor of CYP2D6. The FDA label states that co-administration of bupropion with desipramine (a CYP2D6 substrate) increases desipramine AUC by approximately 5-fold [3]. This inhibition is clinically relevant for drugs like metoprolol, tamoxifen, codeine, and certain antipsychotics. It is not clinically relevant for spironolactone because spironolactone clearance does not depend on CYP2D6 activity.

Net Pharmacokinetic Effect

No published pharmacokinetic interaction study exists for this specific drug pair. Based on metabolic pathway analysis, the expected pharmacokinetic interaction magnitude is negligible. Neither drug alters the plasma concentration of the other to a degree that would require dose modification.

Pharmacodynamic Considerations

While the pharmacokinetic interaction is minimal, pharmacodynamic overlap requires clinical attention in three domains.

Electrolyte Effects and Seizure Threshold

Spironolactone is a potassium-sparing diuretic. Hyperkalemia is its most serious adverse effect, occurring in approximately 2 to 9% of patients depending on dose and renal function [5]. Bupropion lowers the seizure threshold in a dose-dependent manner, with seizure incidence approximately 0.4% at doses up to 450 mg/day [3].

The connection: severe electrolyte disturbances (hyponatremia, hypokalemia, or rapid shifts) can independently lower seizure threshold. While spironolactone causes hyperkalemia rather than hypokalemia, any patient on a potassium-sparing diuretic who develops intercurrent illness (vomiting, diarrhea) may experience rapid electrolyte flux. This theoretical scenario could compound bupropion's seizure risk.

Blood Pressure Interactions

Spironolactone reduces blood pressure by 10 to 25 mmHg systolic in hypertensive patients (PATHWAY-2 trial, N=335) [6]. Bupropion, conversely, may increase blood pressure by 1 to 7 mmHg in some patients, particularly at higher doses. The GATLAS analysis found mean systolic BP increase of 1.3 mmHg with bupropion compared to placebo [7]. These effects partially offset each other, but the net direction depends on dose and patient characteristics. Blood pressure monitoring at 2 and 4 weeks after initiating co-therapy is reasonable.

QTc Interval

Neither spironolactone nor bupropion carries a significant QTc prolongation risk at therapeutic doses. Bupropion is associated with QTc changes only at supratherapeutic concentrations (overdose scenarios). This is not a clinically meaningful concern when both drugs are dosed within approved ranges.

Monitoring Protocol for Co-Prescribed Patients

A structured monitoring approach reduces the already-low risk associated with this combination.

Baseline Assessment

Before starting both medications concurrently, obtain: serum potassium, sodium, creatinine, eGFR, and blood pressure. Document seizure history. The bupropion FDA label contraindicates its use in patients with seizure disorders, eating disorders (bulimia/anorexia), or those undergoing abrupt discontinuation of alcohol or sedatives [3].

First-Month Monitoring

Recheck potassium and renal function at 4 weeks. If spironolactone dose exceeds 100 mg daily or the patient has eGFR <60 mL/min/1.73m², check potassium at 1 week as well. Monitor blood pressure at each visit. Ask about new-onset headaches, dizziness, or tremor that might signal electrolyte shifts.

Ongoing Monitoring

After stabilization, the American Heart Association recommends potassium monitoring every 3 to 6 months for patients on mineralocorticoid receptor antagonists [8]. No additional monitoring burden is required specifically because of bupropion co-administration.

When to Hold or Adjust

Hold spironolactone if potassium exceeds 5.5 mEq/L. Reduce bupropion dose if systolic blood pressure rises above 160 mmHg or if the patient develops new tremor or myoclonus (potential early seizure-threshold signals). Neither scenario is caused by the interaction itself but rather represents expected adverse-effect profiles of each drug independently.

Dose Considerations

No dose adjustment of either drug is required based on the interaction alone.

Spironolactone Dosing for Acne

Standard acne dosing ranges from 50 to 200 mg daily. Most dermatologists initiate at 50 mg and titrate to 100 mg at 6 to 8 weeks if response is inadequate. A 2024 systematic review (N=2,834 across 30 studies) found that 100 mg daily produced acne improvement in 75 to 100% of patients [9]. These doses remain appropriate regardless of bupropion co-therapy.

Bupropion Dosing

Standard antidepressant dosing for bupropion XL is 150 to 300 mg daily, with a maximum of 450 mg daily. For smoking cessation (Zyban), the standard regimen is 150 mg twice daily for 7 to 12 weeks. No modification is needed when spironolactone is added.

CYP2D6 Poor Metabolizers

One scenario where prescribers should exercise additional caution: patients who are CYP2D6 poor metabolizers already have reduced clearance of CYP2D6 substrates. Adding bupropion (a CYP2D6 inhibitor) in such patients creates a phenocopy of ultralow CYP2D6 activity. While this does not affect spironolactone directly, if the patient is also taking a third medication that is a CYP2D6 substrate (metoprolol, for example), the three-drug interaction becomes clinically meaningful. Always review the full medication list.

Spironolactone Drug Interactions That Matter More

While bupropion is a low-risk combination partner, other drugs commonly co-prescribed deserve greater vigilance.

ACE Inhibitors and ARBs

The combination of spironolactone with lisinopril, ramipril, losartan, or valsartan significantly increases hyperkalemia risk. The RALES trial (N=1,663) established spironolactone's mortality benefit in heart failure but also documented hyperkalemia rates of 2% vs. 1% placebo even with careful monitoring [10]. Real-world data show higher rates when monitoring is less rigorous. Potassium should be checked within 3 days of initiation when these are combined.

NSAIDs

Ibuprofen, naproxen, and other NSAIDs reduce renal prostaglandin synthesis, impairing potassium excretion. Co-prescription with spironolactone raises hyperkalemia risk meaningfully. A Danish cohort study (N=467,000) found that triple therapy (RAAS inhibitor + diuretic + NSAID) increased acute kidney injury risk by 31% [11].

Potassium Supplements and Salt Substitutes

Potassium chloride supplements or potassium-containing salt substitutes (KCl-based) combined with spironolactone can produce dangerous hyperkalemia. The FDA label explicitly warns against routine potassium supplementation during spironolactone therapy [2].

Trimethoprim

Trimethoprim (in Bactrim/Septra) blocks the epithelial sodium channel similarly to amiloride and can cause significant hyperkalemia when added to spironolactone. A population-based study found a 6.7-fold increased risk of hyperkalemia-related hospitalization when trimethoprim was added to spironolactone [12].

Patient Counseling Points

Patients taking both medications should receive specific guidance.

What to Tell Patients

Explain that these two medications do not directly interfere with each other. The combination is considered safe by standard interaction databases. Advise patients to maintain consistent hydration. Report any muscle weakness, irregular heartbeat, or confusion (hyperkalemia symptoms). Report seizure-like episodes (though risk is not increased by the combination at standard doses). Avoid abrupt alcohol cessation without medical supervision while on bupropion.

Dietary Guidance

Patients on spironolactone should avoid excessive potassium intake from foods (bananas, oranges, potatoes, tomatoes) only if their potassium runs at the high end of normal (above 5.0 mEq/L). For patients with normal renal function on standard acne doses (50 to 100 mg), dietary restrictions are generally unnecessary. The 2017 Endocrine Society guidelines note that hyperkalemia risk is low in young women with normal renal function taking spironolactone for androgen-excess conditions [13].

Pregnancy Considerations

Spironolactone is Category C (formerly) and carries a known anti-androgenic risk to male fetuses. Bupropion has a relatively favorable reproductive safety profile compared to some alternatives. Women of reproductive age on both medications must use reliable contraception. If pregnancy is planned, spironolactone must be discontinued at least one month before conception attempts.

Clinical Bottom Line

The spironolactone-bupropion combination carries no established pharmacokinetic interaction and only theoretical pharmacodynamic overlap of low clinical significance. The 2024 American Academy of Dermatology guidelines on hormonal therapy for acne do not list bupropion among drugs requiring dose adjustment or avoidance with spironolactone [14]. Prescribe both at standard doses. Check potassium at baseline and 4 weeks. Monitor blood pressure. Review the complete medication list for higher-risk interactions (ACE inhibitors, ARBs, NSAIDs, trimethoprim, potassium supplements) that genuinely threaten patient safety.